Company facts
- Industry
- Pharmaceutical Preparations
- Headquarters
- South San Francisco, California
- Most recent report
- 8-K, filed Sep 8, 2026
- Incorporated
- Delaware
- Filings on record
- 177 filings
- On EDGAR
- CIK 1869105
- Fiscal year ends
- December
- Filer status
- Emerging growth company
Financials 8 of 10
News 8 of 19
Prospectuses and Registrations 8 of 27
- S-3 Shelf registration statement Sep 1, 2026
- POS AM Post-effective amendment to a registration Sep 1, 2026
- 424B3 Prospectus supplement for an offering Aug 12, 2026
- 424B3 Prospectus supplement for an offering Jun 22, 2026
- 424B3 Prospectus supplement for an offering May 13, 2026
- 424B3 Prospectus supplement for an offering May 6, 2026
- POS AM Post-effective amendment to a registration Apr 30, 2026
- 424B3 Prospectus supplement for an offering Apr 29, 2026
Proxies 2
Ownership 8 of 82
- 4 Insider reported a trade Jul 6, 2026
- 4 Insider reported a trade Jul 6, 2026
- 4 Insider reported a trade Jul 6, 2026
- 4 Insider reported a trade Jul 6, 2026
- SCHEDULE 13D/A Large holder reported an active stake, amended Jul 6, 2026
- 4 Insider reported a trade Jul 6, 2026
- 4 Insider reported a trade Jun 18, 2026
- 4 Insider reported a trade Jun 18, 2026
Other 8 of 37
- EFFECT Notice that a registration became effective Sep 8, 2026
- EFFECT Notice that a registration became effective May 4, 2026
- ARS Annual report sent to shareholders Apr 28, 2026
- EFFECT Notice that a registration became effective Sep 10, 2025
- CORRESP Reply to SEC staff Sep 8, 2025
- UPLOAD Comment letter from SEC staff Sep 3, 2025
- EFFECT Notice that a registration became effective Aug 19, 2025
- 425 Aug 4, 2025
Everything here comes from BridgeBio Oncology Therapeutics, Inc.'s own filings on SEC EDGAR. The filing list is rechecked every hour.